These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29530714)

  • 41. Development and optimization of lyophilized orally disintegrating tablets using factorial design.
    Ahmed IS; Shamma RN; Shoukri RA
    Pharm Dev Technol; 2013; 18(4):935-43. PubMed ID: 22107175
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Formulation studies for mirtazapine orally disintegrating tablets.
    Yıldız S; Aytekin E; Yavuz B; Bozdağ Pehlivan S; Ünlü N
    Drug Dev Ind Pharm; 2016; 42(6):1008-17. PubMed ID: 26530146
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization, optimisation and process robustness of a co-processed mannitol for the development of orally disintegrating tablets.
    Soh JL; Grachet M; Whitlock M; Lukas T
    Pharm Dev Technol; 2013 Feb; 18(1):172-85. PubMed ID: 22582882
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Formulation and evaluation of bitter taste-masked orally disintegrating tablets of high memantine hydrochloride loaded granules coated with polymer via layering technique.
    Kadota K; Terada H; Fujimoto A; Nogami S; Uchiyama H; Tozuka Y
    Int J Pharm; 2021 Jul; 604():120725. PubMed ID: 34029663
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro characterization and mouthfeel study of functionalized calcium carbonate in orally disintegrating tablets.
    Wagner-Hattler L; Wyss K; Schoelkopf J; Huwyler J; Puchkov M
    Int J Pharm; 2017 Dec; 534(1-2):50-59. PubMed ID: 28987455
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development and optimization of dextromethorphan hydrobromide oral disintegrating tablets: effect of formulation and process variables.
    Mostafa HF; Ibrahim MA; Sakr A
    Pharm Dev Technol; 2013; 18(2):454-63. PubMed ID: 22881389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of non-water-soluble placebo pellets of different sizes on the characteristics of orally disintegrating tablets manufactured by freeze-drying.
    Stange U; Führling C; Gieseler H
    J Pharm Sci; 2013 Jun; 102(6):1786-1799. PubMed ID: 23568590
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence-based nanoscopic and molecular framework for excipient functionality in compressed orally disintegrating tablets.
    Al-Khattawi A; Alyami H; Townsend B; Ma X; Mohammed AR
    PLoS One; 2014; 9(7):e101369. PubMed ID: 25025427
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Preparation and evaluation of taste masked orally disintegrating tablets with granules made by the wet granulation method].
    Kawano Y; Ito A; Sasatsu M; Machida Y; Onishi H
    Yakugaku Zasshi; 2010 Dec; 130(12):1737-42. PubMed ID: 21139401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Formulation study for orally disintegrating tablet using partly pregelatinized starch binder.
    Mimura K; Kanada K; Uchida S; Yamada M; Namiki N
    Chem Pharm Bull (Tokyo); 2011; 59(8):959-64. PubMed ID: 21804239
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Compressed orally disintegrating tablets: excipients evolution and formulation strategies.
    Al-khattawi A; Mohammed AR
    Expert Opin Drug Deliv; 2013 May; 10(5):651-63. PubMed ID: 23387409
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Promising Single Oral Disintegrating Tablet for Co-Delivery of Pitavastatin Calcium and Lornoxicam Using Co-Processed Excipients: Formulation, Characterization and Pharmacokinetic Study.
    Teaima MH; Abdel-Haleem KM; Osama R; El-Nabarawi MA; Elnahas OS
    Drug Des Devel Ther; 2021; 15():4229-4242. PubMed ID: 34675486
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Microparticle surface layering through dry coating: impact of moisture content and process parameters on the properties of orally disintegrating tablets.
    Alyami H; Koner J; Dahmash EZ; Bowen J; Terry D; Mohammed AR
    J Pharm Pharmacol; 2017 Jul; 69(7):807-822. PubMed ID: 27696423
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A pharmaceutical study on chlorzoxazone orodispersible tablets: formulation, in-vitro and in-vivo evaluation.
    Moqbel HA; ElMeshad AN; El-Nabarawi MA
    Drug Deliv; 2016 Oct; 23(8):2998-3007. PubMed ID: 26828616
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin.
    Salmani JM; Lv H; Asghar S; Zhou J
    Pharm Dev Technol; 2015 Jun; 20(4):465-72. PubMed ID: 24490758
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differences in fundamental and functional properties of HPMC co-processed fillers prepared by fluid-bed coating and spray drying.
    Dong Q; Zhou M; Lin X; Shen L; Feng Y
    Eur J Pharm Sci; 2018 Jul; 119():147-158. PubMed ID: 29626592
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of granule properties on rough mouth feel and palatability of orally disintegrating tablets.
    Kimura S; Uchida S; Kanada K; Namiki N
    Int J Pharm; 2015 Apr; 484(1-2):156-62. PubMed ID: 25681720
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An in vitro analysis of disintegration times of different formulations of olanzapine orodispersible tablet: a preliminary report.
    Hobbs D; Karagianis J; Treuer T; Raskin J
    Drugs R D; 2013 Dec; 13(4):281-8. PubMed ID: 24170256
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel spray-dried nanoparticles-in-microparticles system for formulating scopolamine hydrobromide into orally disintegrating tablets.
    Li FQ; Yan C; Bi J; Lv WL; Ji RR; Chen X; Su JC; Hu JH
    Int J Nanomedicine; 2011; 6():897-904. PubMed ID: 21720502
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Orally disintegrating tablets and orally disintegrating mini tablets - novel dosage forms for pediatric use.
    Comoglu T; Dilek Ozyilmaz E
    Pharm Dev Technol; 2019 Sep; 24(7):902-914. PubMed ID: 31215850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.